Panagi Z - Search Results

1

PLA and PLGA microspheres of beta-galactosidase: Effect of formulation factors on protein antigenicity and immunogenicity.

Stivaktakis N, Nikou K, Panagi Z, Beletsi A, Leondiadis L, Avgoustakis K. Stivaktakis N, et al. Among authors: panagi z. J Biomed Mater Res A. 2004 Jul 1;70(1):139-48. doi: 10.1002/jbm.a.30085. J Biomed Mater Res A. 2004. PMID: 15174118

2

Immune responses in mice of beta-galactosidase adsorbed or encapsulated in poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres.

Stivaktakis N, Nikou K, Panagi Z, Beletsi A, Leondiadis L, Avgoustakis K. Stivaktakis N, et al. Among authors: panagi z. J Biomed Mater Res A. 2005 Jun 1;73(3):332-8. doi: 10.1002/jbm.a.30300. J Biomed Mater Res A. 2005. PMID: 15793820

3

Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.

Beletsi A, Panagi Z, Avgoustakis K. Beletsi A, et al. Among authors: panagi z. Int J Pharm. 2005 Jul 14;298(1):233-41. doi: 10.1016/j.ijpharm.2005.03.024. Int J Pharm. 2005. PMID: 15936907

4

Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles.

Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. Panagi Z, et al. Int J Pharm. 2001 Jun 19;221(1-2):143-52. doi: 10.1016/s0378-5173(01)00676-7. Int J Pharm. 2001. PMID: 11397575

5

PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties.

Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. Avgoustakis K, et al. Among authors: panagi z. J Control Release. 2002 Feb 19;79(1-3):123-35. doi: 10.1016/s0168-3659(01)00530-2. J Control Release. 2002. PMID: 11853924

6

Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles.

Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Livaniou E, Evangelatos G, Ithakissios DS. Avgoustakis K, et al. Among authors: panagi z. Int J Pharm. 2003 Jun 18;259(1-2):115-27. doi: 10.1016/s0378-5173(03)00224-2. Int J Pharm. 2003. PMID: 12787641

7

Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses.

Mattheolabakis G, Lagoumintzis G, Panagi Z, Papadimitriou E, Partidos CD, Avgoustakis K. Mattheolabakis G, et al. Among authors: panagi z. Int J Pharm. 2010 Jan 29;385(1-2):187-93. doi: 10.1016/j.ijpharm.2009.10.033. Epub 2009 Oct 27. Int J Pharm. 2010. PMID: 19874877

8

Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.

Li M, Panagi Z, Avgoustakis K, Reineke J. Li M, et al. Among authors: panagi z. Int J Nanomedicine. 2012;7:1345-56. doi: 10.2147/IJN.S23758. Epub 2012 Mar 7. Int J Nanomedicine. 2012. PMID: 22419876 Free PMC article.

9

Development of biodegradable controlled release scleral systems of triamcinolone acetonide.

Blatsios G, Tzimas AS, Mattheolabakis G, Panagi Z, Avgoustakis K, Gartaganis SP. Blatsios G, et al. Among authors: panagi z. Curr Eye Res. 2010 Oct;35(10):916-24. doi: 10.3109/02713683.2010.497599. Curr Eye Res. 2010. PMID: 20858113

10

Improvement of Chemotherapy Solutions Production Procedure in a Hospital Central Chemotherapy Preparation Unit: A Systematic Risk Assessment to Prevent Avoidable Harm in Cancer Patients.

Bourika K, Koutras A, Kalofonos H, Vicha A, Tsiata E, Papadimitriou E, Avgoustakis K, Panagi Z. Bourika K, et al. Among authors: panagi z. Clin Med Insights Oncol. 2019 Jun 10;13:1179554919852933. doi: 10.1177/1179554919852933. eCollection 2019. Clin Med Insights Oncol. 2019. PMID: 31217699 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters